BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront

The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantical...

January 10, 2025 | News

2025 Pharma and Medical Device Trends for Manufacturing Leaders

2025 Pharma and Medical Device Trends for Manufacturing LeadersKey Insights for Regulated Manufacturing Today and Tomorrow In ...

January 07, 2025 | News

25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare

The pharmaceutical industry is bracing for a transformative year as 2025 approaches, with 25 high-revenue drugs set to lose patent protection. These expira...

December 27, 2024 | Analysis

Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025

Antibody-Drug Conjugates (ADCs) represent a paradigm shift in oncology, offering targeted cancer treatment that minimizes collateral damage to healthy cell...

December 23, 2024 | News

Sanofi and Teva Report Positive Phase 2b Results for Duvakitug in Ulcerative Colitis and Crohn’s Disease

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpo...

December 18, 2024 | News

Menarini Group Reports Positive Phase 3 Results for Obicetrapib in Reducing LDL-C Levels

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapie...

December 17, 2024 | News

Novo Holdings Completes Catalent Acquisition; Novo Nordisk Secures Strategic Manufacturing Sites

Analysis of Novo Holdings A/S’s Acquisition of Catalent and Novo Nordisk’s Strategic Expansion The imminent completion of ...

December 16, 2024 | Analysis

ADELA Phase III Trial Combines Elacestrant and Everolimus to Tackle Advanced ER+/HER2- Breast Cancer with ESR1 Mutations

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breas...

December 13, 2024 | News

AstraZeneca and MSD LYNPARZA Shows Sustained Survival Benefit at Six Years in High-Risk Early Breast Cancer

87.5% of patients treated with LYNPARZA were alive at six years vs. 83.2% in the comparator arm First and only PARP inhibitor to improve survival in...

December 12, 2024 | News

IPO Renaissance: Biopharma's Strategic Momentum Sets the Stage for 2025

The IPO class of 2024 has redefined the biopharma and life sciences landscape, marking a return to growth after a prolonged period of market caution. These...

November 27, 2024 | Report

Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds

Life Sciences CEOs bullish on growth prospects and AI investment despite economic challenges Seventy-nine percent of life sciences CEOs are conf...

November 26, 2024 | Report

Special Report: APAC Healthcare Leaders Prioritize Sustainability Amid Global Challenges

Royal Philips , a global leader in health technology, has released the second set of findings from the Asia Pacific (APAC) Future Health Index (FHI) 2024 r...

November 26, 2024 | Report

Roche's Vabysmo Shows Promising Results in Treating Polypoidal Choroidal Vasculopathy in Asian Patients

Roche shared encouraging 16-week interim data from its ongoing Phase 3b/4 SALWEEN trial, revealing significant advancements in vision improvement and...

November 22, 2024 | News

Merck and Abbisko Report Positive Phase III Results for Pimicotinib in TGCT Across Asia, Europe, and North America

Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) ...

November 21, 2024 | News

Stay Connected